Imaging nigral pathology and clinical progression in Parkinson's disease

The pattern of dopamine cell loss in Parkinson's disease (PD) is known to be prominent in the ventrolateral and caudal substantia nigra (SN), but less severe in the dorsal and rostral region. Both diffusion tensor imaging (DTI) and R2* relaxometry of the SN have been reported as potential markers for PD, but their relative ability to mark disease progression and differences in pathophysiological bases remains unclear. High‐resolution T2‐weighted, R2*, and DTI were obtained from 28 controls and 40 PD subjects [15 early stage [disease duration ≤1 year], 14 mid stage [duration 2–5 years], and 11 late stage [duration >5 years]). Fractional anisotropy and R2* values in both rostral and caudal SN were obtained for all subjects, and clinical measures (e.g., disease duration, levodopa‐equivalent daily dosage, and “off”‐drug UPDRS motor score) were obtained for Parkinson's subjects. There was no correlation between fractional anisotropy and clinical measures, whereas R2* was strongly associated with disease progression. Compared to controls, fractional anisotropy in caudal SN was significantly decreased in PD patients of all stages, whereas in rostral SN, it was decreased significantly only in the late‐stage group. R2* in both SN regions was significantly increased in the mid‐ and late‐stage, but not early‐stage, of PD subjects. These findings suggest that fractional anisotropy changes may mark early pathological changes in caudal SN, whereas the changes in R2* may more closely track PD's clinical progression after symptom onset. © 2012 Movement Disorder Society

[1]  Dorothee P Auer,et al.  T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[2]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[3]  Q. Pankhurst,et al.  Looking for biogenic magnetite in brain ferritin using NMR relaxometry , 2005, NMR in biomedicine.

[4]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[5]  Janey Prodoehl,et al.  Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging , 2012, Neurobiology of Aging.

[6]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[7]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[8]  Martin Styner,et al.  Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[9]  E.M. Haacke,et al.  Characterizing the Mesencephalon Using Susceptibility-Weighted Imaging , 2009, American Journal of Neuroradiology.

[10]  M. B. Spraker,et al.  High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease , 2009, Neurology.

[11]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[12]  Alberto Albertini,et al.  Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.

[13]  S Fook-Chong,et al.  Case control study of diffusion tensor imaging in Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[15]  Lisa Kuramoto,et al.  Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. , 2004, Archives of neurology.

[16]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[17]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[18]  A. Lang The progression of Parkinson disease , 2007, Neurology.

[19]  D. Calne,et al.  Patterns of Asymmetry Do Not Change Over the Course of Idiopathic Parkinsonism , 1995, Neurology.

[20]  A. Roch,et al.  Relaxation induced by ferritin and ferritin‐like magnetic particles: The role of proton exchange , 2000, Magnetic resonance in medicine.

[21]  D. Mikulis,et al.  A new sensitive imaging biomarker for Parkinson disease? , 2009, Neurology.

[22]  Paul M. Matthews,et al.  MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study , 2009, NeuroImage.

[23]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[24]  Yi Wang,et al.  Quality control of diffusion weighted images , 2010, Medical Imaging.

[25]  M Schulzer,et al.  Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.

[26]  S. Ropele,et al.  Quantitative MR imaging of brain iron: a postmortem validation study. , 2010, Radiology.

[27]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[28]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[29]  Khader M. Hasan,et al.  Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson’s disease , 2007, Neurobiology of Disease.

[30]  P. Riederer,et al.  Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.

[31]  William W. Boonn,et al.  Medical Imaging 2010: Advanced PACS-based Imaging Informatics and Therapeutic Applications , 2010 .

[32]  Qing X Yang,et al.  MRI and histological analysis of beta‐amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice , 2009, Journal of magnetic resonance imaging : JMRI.

[33]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[34]  Yoshiharu Tamakawa,et al.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.

[35]  Andreas Schäfer,et al.  High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease , 2012, Journal of magnetic resonance imaging : JMRI.

[36]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[37]  E. Bullmore,et al.  Formal characterization and extension of the linearized diffusion tensor model , 2005, Human brain mapping.

[38]  Daniel Rueckert,et al.  Nonrigid registration using free-form deformations: application to breast MR images , 1999, IEEE Transactions on Medical Imaging.

[39]  B. Halliwell Oxygen radicals as key mediators in neurological disease: Fact or fiction? , 1992, Annals of neurology.

[40]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[41]  Z. Cho,et al.  Seven‐tesla magnetic resonance images of the substantia nigra in Parkinson disease , 2012, Annals of neurology.

[42]  A. Stefani,et al.  Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.

[43]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[44]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[45]  T A Yousry,et al.  Anatomy of the substantia nigra and subthalamic nucleus on MR imaging. , 2010, Neuroimaging clinics of North America.

[46]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[47]  E. Haacke,et al.  Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.